Latest News and Press Releases

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma company focused on mitochondrial medicine and protein homeostasis, today welcomes Sheikh...

Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs

Innovate GBM’s 2025 Impact Report highlights $170M in funding commitments, uniting the Community to grow an Ecosystem of innovation and progress.

Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to...

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM) and Topline Phase 2b clinical data expected in 1H 2026

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty...

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO,...

Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO,...